Non-Hodgkin's lymphoma (LNH) is an uncontrolled clonal proliferation of immature lymphoid precursors that lose their differentiation capacity and cause hypertrophy of the lymphatic organ that hosts them. Studying and analyzing the evolution of immunological and immunophenotypic parameters according to the applied treatment regimens demonstrates their predictive values for improving the long-term survival rate and recognizing optimal treatment regimens in order to reduce acute and late complications. Peripheral blood research in patients aged ≥61 years of onset of disease with assessment of humoral homeostasis indices and assessment of lymphoma phenotype by monoclonal antibody monoclonal antibody (AcM) labeling showed the predominance of cell line B antigens compared to cell line T. In addition to these features, AcMs are particularly important for the success of therapy. The use of chimeric or human AcM reduces immune rejection, facilitating effective clinical action. Each Ac specifically recognizes a particular antigenic determinant or epitope to which it binds to a portion having a complementary structure to the epitope. Cyclical monitoring of immunological parameters after each stage of therapeutic protocol termination determines their tendency to decrease and contributes to diminishing the immune response of the host organism. The slightly increased percentage of CD19, CD20 for the given age group determines a sufficiently high density on the target cell will support the effect of obtaining more effective therapeutic response in both monotherapy and combined therapies. Since most AcM-based treatments are dependent on these characteristics, and the immunological characteristics show that with the increase in the number of therapeutic cycles, the immune response of the host organism is reduced, which will induce attenuation of the anti-tumor defense mechanisms.